Setmelanotide

Setmelanotide has been studied in 23 papers since 2021: 1 trial and 5 observational studies in people, 1 in animals, 15 reviews; 9 in the past year. It is an approved medicine. The newest paper, Nov 2, 2026: “Weight-Loss-Enriched Reverse Cardiac Remodeling After Semaglutide and Tirzepatide Initiation on Longitudinal Echocardiography”.

InterventionApproved 2020

23 papers study it5 findingsUpdated

PubChemMeSH

More peptides

1 new paper in 30 daysSee all 23 papers on setmelanotide

At a glance

The findings reach people, from one lab or study. 3 independent labs in 2 countries; 24 trials, none about aging, 3 with no results posted.

“The overall mean (SD) change in MetS-Z-BMI score after ∼1 year of treatment was -1.05 (0.88).”
Impact of setmelanotide on metabolic syndrome risk in patients with proopiomelanocortin or leptin receptor deficienciesThe Journal of clinical endocrinology and metabolism2026doi:10.1210/clinem/dgag345

None of its findings points the other way.

Mice and humans: a single group. Cells and worms or flies: nothing yet.
  • 3 independent labs in 2 countries
  • 24 trials, none about aging, 3 with no results posted
  • Funders: Danish Diabetes Academy and 7 more
  • 2 of 5 findings with company ties
  • 22 of 24 trials sponsored by its developers
  • Human trial1
  • Humans5
  • Animals1

Studies in people

1 study gave setmelanotide to people and measured what changed.

What changedDesignPeopleSource

down: Decreases MetS-Z-BMI scoreMean change -1.05 (SD 0.88)

Trialapproximately 1 year18 peoplePOMC or LEPR deficiencyThe Journal of clinical endocrinology and metabolism, Oct 19, 2026

What did studies of setmelanotide find?

5

Studies of setmelanotide measured 5 outcomes, among them MetS-Z-BMI score, HOMA-IR and liver stiffness.

MetS-Z-BMI score

downin humans1

1 study
  1. Setmelanotide decreases MetS-Z-BMI score in humans (POMC or LEPR deficiency) (Mean change -1.05 (SD 0.88)).

    Human trialPOMC or LEPR deficiencyapproximately 1 yearn = 18

More on MetS-Z-BMI score

HOMA-IR

downin humans1

1 study
  1. Setmelanotide decreases HOMA-IR in humans (Bardet-Biedl syndrome).

    Human trialBardet-Biedl syndrome12 monthsmalesn = 1

More on HOMA-IR

Liver stiffness

downin humans1

1 study
  1. Setmelanotide decreases liver stiffness in humans (Bardet-Biedl syndrome).

    Human trialBardet-Biedl syndrome12 monthsmalesn = 1

More on Liver stiffness

Body weight

downin humans1−11%

1 study
  1. Setmelanotide decreases body weight in humans (Bardet-Biedl syndrome) (-10.5%).

    Human trialBardet-Biedl syndrome12 monthsmalesn = 1

Weight loss

no changein mice1

1 study
  1. Setmelanotide showed no clear effect on weight loss in mice with calorie restriction lead-in.

    Animalswith calorie restriction lead-in7 or 14 days

Has setmelanotide been tested in people?

0 of 24 about aging

Yes: 1 trial and 5 observational studies in people have been published, and 22 trials are registered.

Approved

  • FDA Imcivree

    Nov 25, 2020Bardet-Biedl Syndrome, acquired hypothalamic obesity, monogenic obesity, excess body weight, leptin receptor deficiency

  • EMA Imcivree

    Jul 16, 2021Obesity, Bardet-Biedl Syndrome, acquired hypothalamic obesity, treatment of obesity, leptin receptor deficiency, hunger

Repurposing

All 7

In trials

  • Sexual Infantilism

    Phase 3Completed4 trials

  • Proopiomelanocortin Deficiency

    Phase 3Results posted2 trials

  • Optic nerve hypoplasia

    Phase 3Recruiting1 trial

  • Septo optic dysplasia

    Phase 3Recruiting1 trial

  • Genetic obesity

    Phase 2Results posted1 trial

  • Smith magenis syndrome

    Phase 2Results posted1 trial

Who is developing setmelanotide?

1 company: Rhythm Pharmaceuticals.

Companies
  • Rhythm PharmaceuticalsPhase 4obesity, genetic obesity

Trial sponsors

Latest

Dec 2025: 1Jan 2026: 0Feb 2026: 1Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 2Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 1Nov 2026: 19 papers in 12 months

See all 23 papers on setmelanotide